News
Emblation Appoints Medical Affairs Advisors
October 6, 2026
STIRLING, Scotland and LINCOLN, R.I., 6 October, 2026 — Emblation, the company behind the innovative SwiftPro® microwave therapy system, today announced the appointment of four Medical Affairs Advisors, bringing together distinguished clinicians and podiatry experts who will contribute their experience and perspectives to the company’s clinical education initiatives for its SwiftPro® medical device. SwiftPro recently received FDA 510(k) clearance for the treatment of common and plantar warts.
“We are delighted to have the opportunity to collaborate with these distinguished clinicians,” said Ian Stevens, Chief Executive Officer of Emblation. “Their expertise and experience will be invaluable as we continue to expand peer-to-peer educational initiatives and support the effective use of SwiftPro.”
Unlike traditional wart treatments that damage or surgically remove infected tissue, SwiftPro uses HeatBeat™ microwave therapy to alert the body’s immune system to the viral infection, helping it recognize and fight the virus naturally. As the immune response clears the underlying viral infection, the associated skin lesion is resolved as well. By contrast, traditional treatments physically destroy or excise the wart, but do so without eliminating the underlying virus, which can contribute to recurrence.
The Medical Affairs Advisors will facilitate peer-to-peer educational support, providing clinical perspectives and practical insights to help clinicians optimize their use of SwiftPro. Guidance will also be provided on the use of Swiftscope™, the companion app that enables enhanced visualization, treatment documentation and monitoring of patient progress.
Ivan Bristow, PhD (Dermatol), MSc (Oxon), FRCPodM is an internationally recognized podiatrist, academic, and author based in the United Kingdom, with expertise in podiatric dermatology and skin conditions affecting the lower limb and foot. Dr. Bristow has published more than 140 professional and academic papers and has authored textbooks on foot and ankle disorders. He also leads the Podiatric Dermatology Blog. His current work includes consultancy, research, and private practice. He is an Honorary Professor at Health Sciences University in Dorset, United Kingdom, and holds visiting positions at universities in the UK and Australia.
Robert M. Conenello, DPM is founder of Orangetown Podiatry in New York, where he specializes in sports medicine, lower extremity biomechanics and regenerative medicine. He frequently lectures globally on biomechanics and regenerative medicine. A past President of the American Academy of Podiatric Sports Medicine, Dr. Conenello has extensive experience in non-invasive and innovative treatment approaches and is committed to advancing effective, patient-focused care.
Melissa J. Lockwood, DPM is the founder of Heartland Foot and Ankle Associates, P.C. in Illinois and a podiatric physician and surgeon with extensive experience treating dermatologic conditions of the foot. A nationally recognized speaker on podiatric medicine, Dr. Lockwood is a Fellow and current Chairperson of the American Society of Podiatric Surgeons (ASPS). Her clinical interests include innovative, non-invasive treatment approaches, with a particular focus on dermatological conditions and preventive care.
Tracey C. Vlahovic, DPM is a podiatric physician, clinical professor, and author with extensive experience in podiatric dermatology. Dr. Vlahovic practices at Bay Area Foot Care in San Francisco and currently is professor at Samuel Merritt University College of Podiatric Medicine in Oakland. An international speaker and author, Dr. Vlahovic has published more than 90 peer-reviewed papers addressing lower extremity dermatology, plantar warts, dermoscopy, and nail disorders.
About Emblation
Based in Stirling, Scotland with U.S. headquarters in Lincoln, R.I., Emblation launched Swift in 2016. Since then, over 750,000 treatments have been conducted globally with over 85% of patients experiencing complete resolution and a low recurrence rate compared to traditional methods. The company recently received FDA 510(k) clearance for expanded indications of its Swift and SwiftPro Systems for the treatment of common and plantar warts.
Media Contact:
Emblation
844-793-8776
media@emblation.com
Research
Transcriptomic Profiling of Cutaneous Melanoma Metastases Treated With Microwave Ablation—Pilot Study
June 18, 2026
This pilot study assessed whether microwave energy applied directly to the skin could treat cutaneous melanoma metastases.
Seven adults whose metastases were not resolving on standard treatment received microwave therapy, and their lesions were evaluated morphologically, histologically and through RNA sequencing. Three patients showed a complete response and four a partial response. In complete responders, treatment increased inflammatory and tissue-repair genes (CXCL5, CXCL8, IL1A, COL1A1) and reduced melanoma markers (PRAME, S100B, MLANA, STK32A). Compared with partial responders, they also showed higher FABP4 expression. These findings support further clinical evaluation of microwave therapy for cutaneous melanoma metastases.
Research
Microwave treatment of human papillomavirus-positive in vitro grown epithelial tissues results in a rapid stress-related transcriptional response and induction of innate immunity
June 16, 2026
Hyperthermia is a well-documented adjunct to cancer therapy. Recently, it has begun to gain traction in the treatment of human papillomavirus (HPV)-driven pathologies.
Microwaves offer a precise and targeted approach to deliver hyperthermia and are already in use in the clinic for the treatment of plantar and common warts: non-oncogenic HPV-driven cutaneous lesions.
News
Emblation Announces Strategic Partnership with DermLite to Assist Diagnosis and Documentation of Skin Conditions Treated by Swift Technology
June 4, 2026
Enhanced dermoscopy access now available for clinicians who are using the Swiftscope app.
Emblation, the company behind the innovative Swift® microwave therapy system, has announced a collaboration with DermLite, a global leader in dermatoscope technology. DermLite’s industry-leading dermatoscope – the DL1, will now be available via the Swift store, providing podiatrists with seamless access to advanced diagnostic tools that enhance both clinical decision-making and patient education.
Dermoscopy has long been an essential tool in dermatology and is rapidly gaining traction in other specialties, including podiatry. By enabling close examination of skin lesions, dermatoscopes provide enhanced visualization that helps clinicians distinguish between different conditions and track treatment progress with greater confidence.
“Emblation has recently introduced Swiftscope™, a lesion tracking app designed specifically for SwiftPro® users. Swiftscope integrates digital dermoscopy and smartphone technology to support comparative imaging, establish visual baselines, and monitor treatment progress over time,” said Ian Stevens, CEO of Emblation.
“The partnership with DermLite reflects our shared commitment to equipping healthcare professionals with practical, high-quality tools that improve outcomes and elevate the patient experience.”
Stevens added: “By combining DermLite’s dedication to diagnostic excellence with Emblation’s commitment to innovation we hope to expand access to dermoscopy and support clinicians’ commitment to improving standards of care.”
Emblation
Based in Stirling, Scotland with US headquarters in Lincoln, RI, Emblation launched Swift in 2016. Since then, over 650,000 treatments have been conducted globally with over 85% of patients experiencing complete resolution and a low recurrence rate compared to traditional methods. The company recently received FDA 510(k) clearance for expanded indications of its Swift and SwiftPro Systems for the treatment of common and plantar warts.
About DermLite
Based in California, DermLite is a leading provider of handheld dermatoscopes. Since 2024, DermLite has also been part of the FotoFinder Group. Together, they are shaping the future of skin imaging and creating a comprehensive ecosystem that empowers clinicians with new discoveries and opportunities – enabling more precise diagnoses and the sustainable advancement of skin health.
Media Contact:
Emblation
844-793-8776
media@emblation.com
News
Emblation Launches Swiftscope App for Enhanced Visual Monitoring of SwiftPro Treatments
May 26, 2026
Emblation, the company behind the innovative Swift® microwave therapy system, announced today Tuesday 26 May, 2026 that its Swiftscope app is now available, allowing clinicians to visually track and show treatment progress
The Swiftscope™ app works in tandem with the SwiftPro® microwave device, which recently earned FDA 510(k) clearance for the treatment of common and plantar warts.
“We are pleased to announce the launch of the Swiftscope app, which provides clinicians the ability to capture and compare treatments and visually show their patients to help educate them about their diagnosis and treatment journey,” said Ian Stevens, chief executive officer of Emblation. “The addition of the Swiftscope app is part of our ongoing commitment to support clinicians and patients globally with tools that strengthen confidence, trust and clinical outcomes.”
Unlike traditional methods that can cause damage and discomfort, the company’s microwave heat therapy activates the immune system to clear skin conditions naturally, delivering better outcomes with less pain than traditional methods, and is safe and more tolerable for patients.
The Swiftscope app allows clinicians to capture consistent images of the condition, compare progress side-by-side, show patients changes at each appointment, and confidently guide patients through treatment. The app integrates with leading smartphone and iPad dermatoscopes, enabling clinicians to capture high-quality clinical and dermoscopic images with seamless documentation.
“Treating common and plantar warts can be a challenging process for patients, often requiring weeks or months of consistent treatment,” said Tracey Vlahovic, DPM, Bay Area Foot Care. With the Swiftscope app, I can show patients exactly how their treatment is working in real-time. Giving patients that visual understanding of progress from the very first appointment keeps them motivated, and it’s incredibly rewarding to hear them say, ‘I can actually see it working.'”
SwiftPro and the Swiftscope app are available in many global markets, including the U.S., U.K., and Canada. For more information visit swiftbyemblation.com.
About Emblation
Based in Stirling, Scotland with U.S. headquarters in Lincoln, R.I., Emblation launched Swift® in 2016. Since then, over 650,000 treatments have been conducted globally with over 85% of patients experiencing complete resolution and a low recurrence rate compared to traditional methods. The company recently received FDA 510(k) clearance for expanded indications of its Swift and SwiftPro® Systems for the treatment of common and plantar warts.
Media Contact:
Emblation
844-793-8776
media@emblation.com
Research
Microwave therapy for the treatment of cutaneous melanoma metastases – A pilot study
March 30, 2026
Malignant melanoma is the UK’s fifth most common cancer, and 10–45% of people with metastatic disease develop cutaneous metastases.
These are currently managed with options ranging from cryotherapy, radiotherapy, laser ablation and electrochemotherapy to immunotherapies such as T-VEC, interleukin-2, nivolumab and ipilimumab. This study, conducted at University Hospital Southampton, tested the Swift® microwave device for treating melanoma metastases. It enrolled adults with stage IV or inoperable stage III cutaneous melanoma who had at least three cutaneous metastases and for whom alternative treatments were unwanted or deemed inappropriate.